Giant Biogene Holding Co., Ltd. (HKG:2367)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 32.19B -58.5% |
| Revenue (ttm) | 6.14B -0.4% |
| Net Income | 2.13B -7.2% |
| EPS | 2.01 -12.1% |
| Shares Out | 1.06B |
| PE Ratio | 15.05 |
| Forward PE | 14.55 |
| Dividend | 1.39 (4.60%) |
| Ex-Dividend Date | Jun 1, 2026 |
| Volume | 4,319,003 |
| Average Volume | 5,602,134 |
| Open | 30.34 |
| Previous Close | 30.32 |
| Day's Range | 30.08 - 31.20 |
| 52-Week Range | 27.20 - 87.10 |
| Beta | 0.72 |
| RSI | 49.38 |
| Earnings Date | May 27, 2026 |
About Giant Biogene Holding
Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People’s Republic of China. It offers functional skincare products, medical dressings and devices, and functional food products under the KOMFYMED, Collgene, Ke Yu, SKIGIN, and other brands. The company also develops and manufactures rare ginsenosides technology-based functional food products. In addition, it provides aesthetic services. The company was founded ... [Read more]
Financial Performance
In 2025, Giant Biogene Holding's revenue was 5.52 billion, a decrease of -0.37% compared to the previous year's 5.54 billion. Earnings were 1.91 billion, a decrease of -7.15%.
Financial numbers in CNY Financial StatementsNews
Giant Biogene Bruised In A 'Battle Of The Skincare Belles'
A squabble involving false advertising claims by a sinking Bloomage Biotech against highflying rival Giant Biogene has captivated China, with no end in sight Key Takeaways: Shares of Giant Biogene hav...